GeNeuro (GNRO) Stock Overview
A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GNRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
GeNeuro SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.031 |
| 52 Week High | €0.18 |
| 52 Week Low | €0.02 |
| Beta | 0 |
| 1 Month Change | 6.94% |
| 3 Month Change | -16.30% |
| 1 Year Change | -78.76% |
| 3 Year Change | -98.29% |
| 5 Year Change | -99.07% |
| Change since IPO | -99.75% |
Recent News & Updates
Shareholder Returns
| GNRO | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | 1.6% |
| 1Y | -78.8% | 302.1% | 1.5% |
Return vs Industry: GNRO underperformed the French Biotechs industry which returned 317.4% over the past year.
Return vs Market: GNRO underperformed the French Market which returned 0.4% over the past year.
Price Volatility
| GNRO volatility | |
|---|---|
| GNRO Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: GNRO's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: GNRO's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Jesus Martin-Garcia | www.geneuro.com |
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program.
GeNeuro SA Fundamentals Summary
| GNRO fundamental statistics | |
|---|---|
| Market cap | €911.56k |
| Earnings (TTM) | -€14.76m |
| Revenue (TTM) | n/a |
Is GNRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNRO income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €14.76m |
| Earnings | -€14.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GNRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/04 17:13 |
| End of Day Share Price | 2026/02/04 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeNeuro SA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Lefebvre | Gilbert Dupont |
| Delphine Le Louet | Societe Generale Cross Asset Research |
| Eric Le Berrigaud | Stifel, formerly Bryan Garnier |